EC-70124

EC-70124 is a **novel, orally bioavailable, multi-kinase inhibitor** derived from the indolocarbazole chemical space, structurally related to midostaurin but with a more focused kinase inhibition profile. It is designed to inhibit several critical oncogenic kinases, notably **FLT3 (FMS-like tyrosine kinase 3)** including FLT3-ITD mutants, **PIM kinases**, and other kinases involved in tumor proliferation and survival, such as those in the PI3K/AKT/mTOR, JAK/STAT, and NF-κB pathways. EC-70124 has demonstrated selective and potent activity in preclinical models of acute myeloid leukemia (AML), especially FLT3-ITD mutant AML, as well as efficacy in various solid tumor models including sarcoma, glioblastoma, prostate, colorectal, and breast cancer. EC-70124 induces cell cycle arrest and apoptosis, blocks key signaling nodes (pSTAT5, pBAD, mTOR-S6, p4EBP1, pAKT, pSTAT3, IKKβ/NF-κB), inhibits cancer stem cell properties, and is able to reverse drug resistance mediated by ABC transporters. The developer is EntreChem, with AML as the lead indication in clinical development[1][2][3][4][5][11].